When methotrexate fails to control rheumatoid arthritis, patients can add other disease modifying drugs or opt for more expensive biological treatments that inhibit tumour necrosis factor. Both worked equally well in a new head to head trial comparing additional …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.